Free Trial

Diaceutics (LON:DXRX) Sets New 12-Month High - Here's What Happened

Diaceutics logo with Medical background

Shares of Diaceutics PLC (LON:DXRX - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 136 ($1.68) and last traded at GBX 136 ($1.68), with a volume of 101158 shares traded. The stock had previously closed at GBX 125.50 ($1.55).

Wall Street Analysts Forecast Growth

DXRX has been the topic of several research analyst reports. Canaccord Genuity Group reiterated a "buy" rating and set a GBX 160 ($1.98) price target on shares of Diaceutics in a research note on Tuesday, December 17th. Canaccord Genuity Group reiterated a "buy" rating and issued a GBX 160 ($1.98) target price on shares of Diaceutics in a research report on Tuesday, December 17th.

Get Our Latest Stock Report on DXRX

Diaceutics Trading Up 8.4 %

The stock has a market cap of £114.88 million, a PE ratio of -4,533.33 and a beta of 0.58. The company's fifty day moving average is GBX 120.33 and its 200-day moving average is GBX 125.86. The company has a debt-to-equity ratio of 2.93, a current ratio of 4.85 and a quick ratio of 9.92.

Diaceutics Company Profile

(Get Free Report)

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

See Also

Should You Invest $1,000 in Diaceutics Right Now?

Before you consider Diaceutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.

While Diaceutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines